Evidence map›Paper›PMID 29257103›Full record

ArticleViruses2017

Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy.

Brunna M Alves, Juliana D Siqueira, Marianne M Garrido, Ornella M Botelho, Isabel M Prellwitz, Sayonara R Ribeiro, Esmeralda A Soares, Marcelo A Soares

Abstract read
In one paragraph

Article in Viruses, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brunna M AlvesPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro 20231-050, Brazil. brunna_alves@yahoo.com.br.
Juliana D SiqueiraPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro 20231-050, Brazil. sidoju@hotmail.com.
Marianne M GarridoServiço de Doenças Infecciosas, Hospital Federal de Ipanema, Rio de Janeiro 22411-020, Brazil. marianne.monteiro@inca.gov.br.
Ornella M BotelhoPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro 20231-050, Brazil. ornellamartins@hotmail.com.
Isabel M PrellwitzPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro 20231-050, Brazil. imprellwitz@gmail.com.
Sayonara R RibeiroServiço de Doenças Infecciosas, Hospital Federal de Ipanema, Rio de Janeiro 22411-020, Brazil. sayorib@gmail.com.
Esmeralda A SoaresPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro 20231-050, Brazil. esoares@inca.gov.br.
Marcelo A SoaresPrograma de Oncovirologia, Instituto Nacional de Câncer, Rio de Janeiro 20231-050, Brazil. masoares@inca.gov.br.ORCID 0000-0002-9013-2570

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased access to highly active antiretroviral therapy (HAART) by human immunodeficiency virus postive (HIV⁺) individuals has become a reality worldwide. In Brazil, HAART currently reaches over half of HIV-infected subjects. In the context of a remarkable HIV-1 genetic variability, highly related variants, called quasispecies, are generated. HIV quasispecies generated during infection can influence virus persistence and pathogenicity, representing a challenge to treatment. However, the clinical relevance of minority quasispecies is still uncertain. In this study, we have determined the archived proviral sequences, viral subtype and drug resistance mutations from a cohort of HIV⁺ patients with undetectable viral load undergoing HAART as first-line therapy using next-generation sequencing for near full-length virus genome (NFLG) assembly. HIV-1 consensus sequences representing NFLG were obtained for eleven patients, while for another twelve varying genome coverage rates were obtained. Phylogenetic analysis showed the predominance of subtype B (83%; 19/23). Considering the minority variants, 18 patients carried archived virus harboring at least one mutation conferring antiretroviral resistance; for six patients, the mutations correlated with the current ARVs used. These data highlight the importance of monitoring HIV minority drug resistant variants and their clinical impact, to guide future regimen switches and improve HIV treatment success.

Indexed as

Antiretroviral Therapy, Highly ActiveQuasispeciesAnti-Retroviral AgentsBrazilGenome, ViralHIV-1HIV InfectionsHumansProvirusesSequence Analysis, DNAViral LoadWhole Genome SequencingAnti-Retroviral Agentsdrug resistanceHAARTHIV-1minority resistance mutationsquasispeciesundetectable viral load

Identifiers

PMID29257103
PMCPMC5744166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.